Post by Alira Health

Market access is becoming a primary determinant of success in nuclear medicine, rather than a downstream consideration. In our latest white paper, we explore how pricing and access strategies are evolving across the US and Europe—and what this means for lifecycle management. For industry leaders, it underscores the importance of integrating access considerations early across development, evidence generation, and commercial strategy to drive scalable, sustainable growth.   Read the paper here: https://lnkd.in/efaUJ22c   To explore these topics further, connect with the authors Irene Lizano, PhD and Sandra Walsh Capdevila, Ph.D..   For those attending the 2026 SNMMI Annual Meeting, our colleagues Piergiulio Lauriano, Akash N Karopadi, and Andrew Moore will be there to discuss how we help navigate diverse regulatory landscapes, complex payer environments, and varying levels of nuclear medicine maturity across geographies.